Zevra has obtained access to Acer’s rare disease assets Olpruva and Edsivo. Zevra Therapeutics has concluded its takeover of complete outstanding shares of Acer Therapeutics to form a rare disease company in a $91m deal. Zevra has obtained access to Acer’s rare...

    Alkermes plc, had announced that it has entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland to Novo Nordisk, a leading global healthcare company. Under the terms of the agreement, upon the closing of the...

  Rain Oncology Inc, had announced that it has entered into a definitive merger agreement whereby Pathos AI, Inc. will acquire Rain Oncology. Privately held Pathos AI, a company focused on leveraging machine learning and real-world data in drug development, will make a cash...

Bristol Myers Squibb had announced a definitive merger agreement under that it will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was unanimously approved by both...

Ajinomoto has signed a definitive agreement for the acquisition of contract development and manufacturing organisation and clinical-stage therapeutics company Forge Biologics in an all-cash transaction totalling $620m. The prospective takeover is part of Ajinomoto’s strategy to...

Bristol Myers Squibb (BMS) has signed a definitive agreement for the acquisition of all of outstanding shares of Mirati Therapeutics in a $5.8bn deal. The company plans to buy Mirati for $58 for each share in cash, representing an equity value of $4.8bn. Mirati shareholders will also...

Eli Lilly and Company has signed a definitive agreement for the acquisition of all outstanding shares of radiopharmaceutical company POINT Biopharma for an all-in cash price of $1.4bn. Lilly offered $12.5 for each share of POINT. POINT’s pipeline comprises radioligand cancer...

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it has entered into a definitive agreement with a newly established portfolio company of Syncona Ltd (LON: SYNC), a leading life science investor focused on creating, building and scaling global leaders in life...

  The Danish drug maker plans to pay up to $2.7bn to Flagship Pioneering-incubated Valo Health for its AI-enabled small molecule discovery and human genetic data platform. Novo Nordisk gets a license to three preclinical-stage cardiovascular disease programmes from Valo Health...

  Sandoz, a global leader in generic and biosimilar medicines, announced that it has entered into a development and commercialization agreement with Samsung Bioepis. The agreement provides Sandoz with the exclusive rights to commercialize the biosimilar SB17 ustekinumab in the...